Clinical Trials Logo

Keratitis clinical trials

View clinical trials related to Keratitis.

Filter by:

NCT ID: NCT04130802 Completed - Pain, Postoperative Clinical Trials

OCS-01 in Treating Inflammation and Pain in Post-cataract Patients

SKYGGN
Start date: September 27, 2019
Phase: Phase 2
Study type: Interventional

The DX-216 trial is a randomized, double-masked, placebo (vehicle)-controlled study evaluating the efficacy and safety of two doses of OCS-01 compared to vehicle in the treatment of inflammation and pain following cataract surgery. The primary objective is to evaluate the efficacy and safety of OCS-01 compared to placebo and the secondary objective is to evaluate the optimal dosing frequency (once a day [QD] or twice a day [BID]).

NCT ID: NCT04097730 Active, not recruiting - Keratitis Bacterial Clinical Trials

Steroids and Cross-linking for Ulcer Treatment

SCUT II
Start date: September 24, 2020
Phase: Phase 3
Study type: Interventional

Steroids and Cross-linking for Ulcer Treatment (SCUT II) is an international, randomized, double-masked, clinical trial. The purpose of this study is to determine differences in 6-month visual acuity between medical antimicrobial treatments alone versus antimicrobial treatment plus collagen cross-linking (CXL), as well as to further evaluate findings from subgroup analyses of SCUT. Patients presenting to the Aravind Eye Care System (India), Kaiser Permanente Northern California (USA), or the University of California, San Francisco (USA) with smear-positive and/or culture-positive typical (i.e. non-Nocardia or Mycobacteria) bacterial corneal ulcers and moderate to severe vision loss, defined as Snellen visual acuity of 20/40 or worse, will be eligible for inclusion. Those who agree to participate will be randomized to one of three treatment groups: Group 1: Standard therapy, topical 0.5% moxifloxacin plus topical placebo plus sham CXL Group 2: Early steroids, topical 0.5% moxifloxacin plus topical difluprednate 0.05% plus sham CXL Group 3: CXL plus early steroids, topical 0.5% moxifloxacin plus topical difluprednate 0.05% plus CXL

NCT ID: NCT04075669 Recruiting - Corneal Ulcer Clinical Trials

Multiplex Strip Polymerase Chain Reaction for Diagnosis of Eye Infection Diseases From Corneal Scraping Samples

Start date: August 1, 2019
Phase:
Study type: Observational

The aim of this study is to see if multiplex strip PCR will detect the pathogen that causing eye infection from the corneal scraping samples with higher sensitivity and specificity than the current gold standard.

NCT ID: NCT04030403 Completed - Clinical trials for Infectious Keratitis

Investigation of the Microbiome of the Cornea in Microbial Keratitis

STOICA
Start date: September 10, 2019
Phase:
Study type: Observational

Design: Prospective observational diagnostic study and methods-comparison. Aims: The overall aim of the project is to better define the pathogenic microorganisms in patients with microbial keratitis (MK) through a better understanding of the corneal and ocular surface microbiome in health and disease. This will be achieved through the following objectives: 1. Using NGS, analyse the corneal microbiome of the affected and unaffected eye of patients with and without MK and compare with simultaneous results from CDC and MTPCR. 2. Determine the microbiological spectrum of the cornea, ocular surface and contiguous structures, in patients with MK, healthy controls, contact lens wearers and eye drop users. Outcome measures: 1. A comparison of isolation rates and identified bacteria obtained from CDC, MTPCR and NGS processing of MK corneal samples will be made. 2. Microorganisms identified in the eyes with MK will be compared to the fellow eye and other control groups and subtractive bioinformatics methodology applied to identify the most likely pathogenic organisms compared to those seen in the healthy corneal and ocular surface microbiome. 3. Comparisons of the relative abundance of microorganisms obtained from MK corneal samples over the participant's follow-up visits will be used to evaluate longitudinal changes in the corneal and ocular surface microbiome during treatment and resolution of MK. 4. A direct comparison between the relative abundance of microorganisms isolated from participants cornea, conjunctiva, eyelids and nose (contiguous structures) will be made to identify any possible endogenous sources of infection for MK. Population Eligibility: - All patients aged 18 years and over presenting with unilateral clinically suspected MK to St. Paul's Eye Unit, The Royal Liverpool University Hospital. - Patients with keratoconus undergoing cross-linking, subjects with no history of MK, subjects with no history of MK who are contact lens wearers and subjects with no history of MK but who are on eye drop treatment for glaucoma. Duration: Three years.

NCT ID: NCT03987178 Completed - Clinical trials for Conjunctivitis, Bacterial

Microbiologic Alterations of the Conjunctiva of Hot Tub-soaking Ophthalmologists

MACHO
Start date: May 27, 2019
Phase: N/A
Study type: Interventional

The purpose of this study is to determine if there are microbiologic alterations of the ocular surface after hot tub exposure. The study will evaluate the number of microbes before and after hot tub use in order to find out whether hot tub exposure has any change on the organisms present on the ocular surface. Participants will be randomized to dunk or not to dunk their head during their time in the hot tub.

NCT ID: NCT03918408 Recruiting - Bacterial Keratitis Clinical Trials

Safety and Effectiveness of the PXL-Platinum 330 System for Corneal Collagen Cross-Linking in Eyes With Corneal Thinning Conditions

Start date: September 1, 2019
Phase: Phase 1
Study type: Interventional

To determine whether the Peschke PXL-330 system is safe and effective in the treatment of corneal thinning conditions.

NCT ID: NCT03845374 Completed - Bacterial Keratitis Clinical Trials

Prospective, Randomized Multi-Center Study of Using the Hyper-CL™ Lens in Subjects Suffering From Bacterial Keratitis

Start date: March 13, 2019
Phase: N/A
Study type: Interventional

This study is a prospective, randomized, open-label, two arms, clinical study aim to evaluate the efficacy and safety of treatment with Hyper-CL™ lens + Antibiotics compared with treatment with Antibiotics only, in subjects with Bacterial keratitis. The design of the Hyper-CL™ lens increases contact time of the antibiotics on the cornea enabling increased bioavailability of the active drug.

NCT ID: NCT03801590 Not yet recruiting - Clinical trials for Infectious Keratitis

Crosslinking in Infectious Keratitis

Start date: December 1, 2021
Phase: N/A
Study type: Interventional

Microbial keratitis is an infection of the cornea that is associated with risk of permanent visual impairment. It can be caused by bacteria, virus, fungus, protozoa and parasites. The common risk factors for infectious keratitis include ocular trauma, contact lens wear, recent ocular surgery, preexisting ocular surface disease, dry eyes, lid deformity, corneal sensation impairment, chronic use of topical steroids and systemic immunosuppression .

NCT ID: NCT03706443 Completed - Dry Eye Syndromes Clinical Trials

Tear Lipid Layer Thickness Changes With Use of Emollient and Non-Emollient Eye Drops

Start date: December 5, 2018
Phase: N/A
Study type: Interventional

Cross-over comparison of lipid layer thickness and dry eye symptoms with two artificial tear formulations.

NCT ID: NCT03652415 Recruiting - Dry Eye Clinical Trials

DRy Eye Outcome and Prescription Study

DROPS
Start date: August 23, 2018
Phase:
Study type: Observational [Patient Registry]

The DRy eye Outcome and Prescription Study (DROPS) is a large observational multicentre study exploring the 'real world' effectiveness of artificial tears in dry eye disease and determinants of efficacy. The aim is to include at least 635 symptomatic dry eye patients who are prescribed artificial tears. All trainees and fellows in London are invited to become collaborators: collaborators are asked to consent patients, assess signs at baseline, and give patients questionnaires at baseline and 4 weeks (for home completion). In tandem, we are conducting a qualitative review of ophthalmologists' prescribing behaviours for dry eye disease.